Expression of apoptosis regulating proteins identifies stage II and III colon cancer patients with high risk of recurrence
Background and Objectives Deregulation of apoptosis related genes may be associated with poor outcome in cancer. Aim of the present study was to investigate the prognostic role of expression levels of apoptosis related proteins in stage II and III colon cancer. Methods From tumor samples of 386 stag...
Saved in:
Published in | Journal of surgical oncology Vol. 109; no. 3; pp. 255 - 265 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.03.2014
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background and Objectives
Deregulation of apoptosis related genes may be associated with poor outcome in cancer. Aim of the present study was to investigate the prognostic role of expression levels of apoptosis related proteins in stage II and III colon cancer.
Methods
From tumor samples of 386 stage II and III colon cancer patients, DNA was isolated and tissue microarrays were constructed. Expression of Bcl‐2, Bcl‐X, BAX, XIAP, Fas, FasL and c‐FLIP was evaluated and PCR‐based microsatellite instability analysis was performed.
Results
High FasL expressing tumors were associated with high disease recurrence rates in stage II colon cancer patients overall, as was low Bcl‐X expression in microsatellite stable stage II patients. In stage II patients, a multivariable model based on FasL and Bcl‐XL expression revealed a significant association with disease free survival (DFS). In stage III colon cancer patients, low Bcl‐2, low BAX and low Fas expression levels were associated with worse outcome. In these patients a multivariable model based on angioinvasion and Bcl‐2, Fas and FasL expression was significantly associated with DFS.
Conclusions
Stage II patients with low Bcl‐X and high FasL protein expression levels and stage III patients with low Fas, high FasL and low Bcl‐2 expression could be considered as high risk for disease recurrence. J. Surg. Oncol. 2014 109:255–265. © 2013 Wiley Periodicals, Inc. |
---|---|
Bibliography: | ark:/67375/WNG-DNGDFVR0-0 ArticleID:JSO23495 istex:E4D6B1A927E6EB15A6737496349DC9C676B21FD6 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0022-4790 1096-9098 |
DOI: | 10.1002/jso.23495 |